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Introduction {#sec1}
============

Retinitis pigmentosa (RP) represents a large class of inherited retinal dystrophies caused by mutations in several families of genes, leading to pigmentary retinopathy and progressive, irreversible blindness. Typically, RP is characterized by the initial loss of rod photoreceptors (PRs), deposition of pigment granules, and peripheral vision loss ([@bib22], [@bib32]). Defective asparagine-linked glycosylation (*N*-glycosylation) of proteins in rod cells, particularly the visual pigment rhodopsin (RHO), results in progressive, irreversible rod cell degeneration and death, with concomitant loss of vision ([@bib52], [@bib53], [@bib37], [@bib24]). Successful glycosylation of RHO is necessary for its vectorial trafficking through the inner segment (cell body) of the rod cell to the site of rod outer segment (ROS) membrane assembly at the base of the ROS. Retinal degeneration has been observed in patients harboring RHO mutations involving the *N*-glycosylation consensus sites, and in animal models involving comparable RHO mutations ([@bib74], [@bib86], [@bib69], [@bib53], [@bib34]), as well as by tunicamycin-induced and genetic inhibition of global/RHO *N*-glycosylation ([@bib23], [@bib26], [@bib62], [@bib72], [@bib53]). Protein *N*-glycosylation involves the following steps (schematic representation, [Figure 1](#fig1){ref-type="fig"}): generation of dolichol (Dol, an important isoprenoid arising from the mevalonate pathway) and dolichyl phosphate (Dol-P, the obligate glycan carrier necessary for *N*-linked glycosylation, *O*-mannosylation, and *C*-mannosylation) ([@bib8], [@bib21], [@bib58], [@bib10], [@bib9], [@bib49], [@bib19]), generation of complex Dol-P-linked oligosaccharides (DLO) ([@bib42], [@bib27], [@bib4]), and transfer of those oligosaccharides from DLO to the *N*-glycosylation consensus site on the target polypeptide ([@bib77]). Genetic defects affecting the glycosylation mechanism constitute a large family of syndromes termed "congenital disorders of glycosylation" (CDGs), with more than 150 causative genes ([@bib54], [@bib67]). A family of genetic diseases pertaining to Dol synthesis is classified as CDG-I (the class of CDG involving defective glycan assembly and/or their transfer in the endoplasmic reticulum \[ER\]) due to the requirement of DLO for *N*-glycosylation. Common clinical features of CDGs include failure to thrive, retarded development, protein-losing enteropathy, early-onset encephalopathy, as well as retinopathies such as RP ([@bib67], [@bib72], [@bib31], [@bib51]).Figure 1Schematic Representation of the Mevalonate Pathway, Dolichol Synthesis, and the Requirement of Dolichyl Phosphate (Dol-P) for N-Linked Oligosaccharide GenerationFarnesyl diphosphate (FPP), an important pre-squalene intermediate of the mevalonate pathway, undergoes DHDDS/NUS1-catalyzed condensation with multiple isopentenyl pyrophosphate (IPP) units to generate polyprenyl pyrophosphate (diphosphate), and ultimately the obligate glycan carrier, Dol-PP. Gene products involved in synthesis of dolichol and Dol-P-saccharide/oligosaccharide intermediates, and hence implicated in CDG-1 (Congenital Disorders of Glycosylation), have been represented. The enzymatic activity provided by DHDDS and NUS1 catalyzes the commitment step of dolichol synthesis; hence mutations in either DHDDS or NUS1 are hypothesized to block protein N-glycosylation, and are classified as CDG-I. Dolichol (*structure in inset*), is an acyclic isoprenoid consisting of 18--21 isoprene units.

Two key intermediate metabolites in the mevalonate pathway, farnesyl pyrophosphate (FPP; also called farnesyl diphosphate) and isopentenyl pyrophosphate (IPP; also called isopentyl diphosphate), serve as precursors for squalene, cholesterol, and Dol synthesis (see [Figure 1](#fig1){ref-type="fig"}) ([@bib28]). The committed enzymatic step in the pathway toward Dol synthesis is the catalytic condensation of FPP with multiple IPP molecules to form polyprenyl diphosphate; this reaction is catalyzed by a *cis*-prenyltransferase (CPT) complex composed of dehydrodolichyl diphosphate synthase (DHDDS) and Nogo-B receptor (NgBR; gene symbol *NUS1*) ([@bib58]). Polyprenyl diphosphate sequentially undergoes dephosphorylation (action of dolichyl diphosphate phosphatase 1 \[DOLPP1\]) ([@bib61]), reduction (action of steroid Δ5 *alpha*-reductase 3 \[SRD5A3\]) ([@bib10]), and phosphorylation (action of dolichol kinase \[DOLK\]) ([@bib65]) to generate Dol-P ([@bib64]). Cellular *de novo* synthesis and availability of Dol-P in the ER ([@bib33], [@bib82], [@bib2]) are necessary for DLO-dependent protein glycosylation ([@bib35]). Genetic defects affecting Dol-P *de novo* synthesis at the level of DHDDS, NgBR, SRD5A3, or DOLK are classified within the CDG-1 subgroup of CDGs ([@bib67], [@bib58]).

Heretofore, animal model or *in vitro* studies have employed approaches such as inhibition of the Dol-P-dependent oligosaccharyltransferase (OST, e.g., using tunicamycin) ([@bib24], [@bib25], [@bib26], [@bib23]) or mutation of the glycosylation consensus sites on specific target proteins (e.g., rhodopsin; [@bib53]) to evaluate the requirement of protein *N*-glycosylation in the retina. Herein, we addressed this requirement by genetic blockade of the rate-limiting step in dolichol synthesis, i.e., the *cis*-prenyltransferase (CPT) activity of DHDDS.

Recent studies involving genetic screening of families with a rare autosomal recessive form of retinitis pigmentosa (RP59) demonstrated a founder missense mutation (K42E) in the *DHDDS* gene ([@bib84], [@bib87]). Two other rare, pathogenic *DHDDS* mutations (T206A, R98W), both found heterozygously with the K42E mutation, also have been reported ([@bib78], [@bib5], [@bib41]). In patients homozygous for the K42E mutation, the peripheral retina underwent thinning, but the cone-rich fovea is well-preserved. Functionally, in one patient examined, dark-adapted ("scotopic," rod-driven) electroretinogrphic (ERG) responses were extinguished by 21--24 years of age, leading to a visual field limited to a small central island, consistent with rod-cone dystrophy or early-onset retinal degeneration. In an infant presenting as a compound heterozygote (W64X and p.Cys148GlufsX11), ERG responses were undetectable at 2 months of age, but the patient died at 7 months of age from multiple systemic complications due to insufficient DHHDS activity ([@bib62]), and thus is distinctly different from the K42E phenotype. The mutations in the *"severe"* phenotype infant led to loss of FPP/IPP-binding sites, much similar to the excision of *Dhdds* Exon 3 used in the current study (see [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2;](#mmc1){ref-type="supplementary-material"} [@bib62]). Retinal degeneration also has been observed in patients of Romani origin harboring mutations in the gene coding for the DHDDS-heterodimeric partner NgBR ([@bib58]). The pathological mechanisms and defective cell processes attributed to RP59, although currently hypothesized to be hypoglycosylation driven, remain to be directly tested. This is largely due to the lack of a validated vertebrate animal model of RP59 to evaluate the link between mammalian *cis*-prenyltransferase DHDDS activity, its requirement for protein *N*-glycosylation, and the establishment and preservation of normal retinal structure and function. Up until recently, only a zebrafish *Dhdds* knockdown model has been reported ([@bib88]; [@bib87]). However, more recently, a report of a K42E knock-in mouse model was published ([@bib59]), but dolichol levels and *cis*-prenyltransferase activity were not examined.

Given this information, we hypothesized that PR-specific deletion of *Dhdds* would elicit a primary PR degeneration owing to the critical requirement of protein *N*-glycosylation for maintenance of PR structure, function, and viability. In the current study, we generated a novel murine, rod PR-specific *Dhdds* knockout model on a C57BL/6J background and examined the functional, morphological, and biochemical consequences to the retina. Contrary to expectation, although a profound retinal degeneration was observed, we found no evidence for defective protein *N*-glycosylation in this mouse model, despite confirmed ablation of *Dhdds* in essentially the entire population of retinal rod cells.

Results {#sec2}
=======

Verification of Rod Photoreceptor-Specific Dhdds Deletion {#sec2.1}
---------------------------------------------------------

A graphical representation of the genotyping strategy utilized for the verification of *Dhdds*^flx/flx^ iCre^+^ mice is provided in [Figures S4](#mmc1){ref-type="supplementary-material"}, [2](#fig2){ref-type="fig"}A, and 2B. Exon 3, coding for critical FPP- and IPP-binding sites, was chosen for targeted deletion ([Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}). Initially, tail snip genotyping analysis was performed to detect floxed *Dhdds* allele and Rho-iCre transgenes: *Dhdds* allele with *loxP* modification and wild-type (WT) *Dhdds* allele yielded 393-bp and 517-bp PCR products, respectively ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4C). Similarly, Rho-iCre transgene yielded a 650-bp PCR product, as shown previously ([Figure S4](#mmc1){ref-type="supplementary-material"}B) ([@bib47]). To further validate excision of the floxed *Dhdds* allele in rod PRs, genomic DNA extracted from *Dhdds*^flx/flx^ iCre^−^ (lanes 2, 4, 6 in [Figure 2](#fig2){ref-type="fig"}C) and *Dhdds*^flx/flx^ iCre^+^ retinas (lanes 1, 3, 5 in [Figure 2](#fig2){ref-type="fig"}C) (n = 3/group) (already verified by tail snip genotyping as demonstrated in [Figure S4](#mmc1){ref-type="supplementary-material"}A and S4B) was subjected to PCR amplification using intronic primers designed upstream and downstream of the targeted exon (see [Figures 2](#fig2){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}C). Genomic material from tail snip genotype-verified *Dhdds*^flx/flx^ iCre^+^ retinas yielded a 650-bp PCR product for Cre recombinase, as previously reported ([@bib47]) (top panel, [Figure 2](#fig2){ref-type="fig"}C), as well as a 584-bp product that corresponds to the remnant intronic region upon excision of exon 3 (middle panel, [Figure 2](#fig2){ref-type="fig"}C) (see [Methods](#sec4){ref-type="sec"} for primer details, and [Discussion](#sec3){ref-type="sec"} for rationale). *Dhdds* WT allele (arising from other retinal cell types) would yield a predicted, larger (1.4 kbp) product (consisting of exon 3 as well as the flanking intronic regions) that is not amplified by a PCR protocol involving a short extension period of 45 s (See [Methods](#sec4){ref-type="sec"}) ([Figures 2](#fig2){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}C). A non-specific, unaltered gene region (*Dhcr7*, 375-bp product) was PCR amplified as a positive control to verify genomic DNA quality (bottom panel, [Figure 2](#fig2){ref-type="fig"}C).Figure 2Verification of Rod Photoreceptor-Specific Deletion of *Dhdds*(A--E) Rod-specific ablation of *Dhdds* was achieved by generating a mouse model harboring homozygous *loxP* sites flanking *Dhdds* exon 3 (gene locus: murine chromosome 4, 66.47 cM\] (A) and cross-breeding against a transgenic mouse line consisting of opsin promoter-driven Cre recombinase (Rho-iCre75, (B)). The cross ultimately generated the knockout line of interest: *Dhdds*^flx/flx^ iCre^+^. *Dhdds*^flx/flx^ iCre^+^ mice were first identified using tail snip genotyping (see also [Figure S4](#mmc1){ref-type="supplementary-material"}). To verify photoreceptor-specific gene excision, whole retinas harvested from mice identified as *Dhdds*^flx/flx^ iCre^+^ and age-matched WT controls were subjected to direct tissue genotyping (C, see also [Figure S4](#mmc1){ref-type="supplementary-material"} for primer design strategy). Retinas from *Dhdds*^flx/flx^ iCre^+^ mice yielded short PCR product (584 bp, *upper panel*, (C) corresponding to the flanking intronic region only (*whitearrow*, B), while positive for Rho-iCre transgene (*middle panel*, C). Control retinal tissue, negative for Cre recombinase (*upper panel*, C), did not exhibit excision of exon 3 (*middle panel*, C). PCR reaction against a housekeeping gene (*Dhcr7*) demonstrates intact genomic content in all biological samples (*bottom panel*, C). Direct tissue genotyping targeting Cre recombinase does not provide morphological context regarding its expression or activity. Rho-iCre75 line was crossed with a ZsGreen reporter mouse: a representative confocal micrograph (D) shows ZsGreen expression exclusively in majority of cells (overwhelmingly rods) in the photoreceptor layer at PN 4 weeks (scale bar, 20 μm). *In situ hybridization* with a probe corresponding to exon 3 of *Dhdds* suggests successful ablation of *Dhdds* in *Dhdds*^flx/flx^ iCre^+^ mice (F), when compared with *Dhdds*^flx/flx^ iCre^−^ mice (E). (Scale bars: 20 μm in (E and F)).

Rod PR-specific excision of *Dhdds* exon 3 is a function of spatiotemporal expression and activity of Cre recombinase (driven by the *Rho* promoter) ([@bib47]). Cre recombinase activity in Rho-iCre75 mice was verified using a reporter mouse strategy. Briefly, the Rho-iCre75 mouse line was crossed with a ZsGreen Ai6 reporter mouse line (harboring CAG artificial promoter-driven ZsGreen \[variant of GFP\]) with an upstream floxed transcriptional termination cassette ([Figure 2](#fig2){ref-type="fig"}D). Cell type/tissue-specific Cre activity, if present, relieves the ZsGreen transcription blockade by excising the upstream, loxP-modified transcription termination cassette, allowing ZsGreen expression. Retinas harvested from the first filial (F~1~) generation of the Rho-iCre-ZsGreen Ai6 reporter mouse crossing at PN 15 days ([Figure S5](#mmc1){ref-type="supplementary-material"}) and PN 30 days (*lower panel*, [Figure 2](#fig2){ref-type="fig"}D) were tested for rod-specific ZsGreen expression using laser confocal fluorescence microscopy. Representative fluorescence micrographs ([Figure 2](#fig2){ref-type="fig"}D) revealed ZsGreen expression in the vast majority of rod PR nuclei by PN 15 and PN 30 days, in good agreement with the published literature ([@bib47]).

Retinal expression of *Dhdds* transcript was directly tested utilizing customized BaseScope *in situ* hybridization (ISH) probes (two ZZ probes) designed against a murine *Dhdds* transcript region corresponding to coding exon 3 (bp 361--455 of [NM_026144.4](ncbi-n:NM_026144.4){#intref0010}). A single mRNA transcript appears as single, red chromogenic dot; bright-field images from ISH experiments in *Dhdds*^flx/flx^ iCre^+^ and *Dhdds*^flx/flx^ iCre^−^ mice ([Figures 2](#fig2){ref-type="fig"}E and 2F, respectively) suggest PR (outer nuclear layer \[ONL\])-specific loss of *Dhdds* transcript (tested at PN 30 days), whereas the adjacent inner nuclear layer (INL) retained a comparable level of ISH label as observed in WT control retinas.

Profound and Rapid Retinal Degeneration and Dysfunction Are Observed in Dhdds^flx/flx^ iCre^+^ Mice {#sec2.2}
---------------------------------------------------------------------------------------------------

Age-matched *Dhdds*^flx/flx^ iCre^−^ and *Dhdds*^flx/flx^ iCre^+^ mice were subjected to *in vivo* retinal imaging and quantitative morphometric analysis using spectral domain optical coherence tomography (SD-OCT). ONL thickness was measured (in mm) around the optic nerve head. [Figure 3](#fig3){ref-type="fig"}A (left panel) shows a set of representative SD-OCT images of retinas from PN 5-week-old controls versus PN 4-, 5-, and 6-week-old *Dhdds*^flx/flx^ iCre^+^ mice. ONL thickness values for PN 4-week-old *Dhdds*^flx/flx^ iCre^+^ mice were comparable to those of control mice at PN 5 weeks of age (see [Figure 3](#fig3){ref-type="fig"}A, right panel). The ONL in the SD-OCT images appears as a hyporeflective region (demarcated by yellow dotted lines, [Figure 3](#fig3){ref-type="fig"}A, left panel). The ONL in *Dhdds*^flx/flx^ iCre^+^ mice underwent significant thinning (*ca*. 50% compared with age-matched controls, n = 4, p \< 0.01) by PN 5 weeks and was essentially absent by PN 6 weeks of age (n = 4, p \< 0.01). A graphical comparison of ONL thickness (in mm) is provided in [Figure 3](#fig3){ref-type="fig"}A (right panel). The SD-OCT data correlate well with results obtained by conventional, paraffin-embedment histological analysis (see [Figures S13](#mmc1){ref-type="supplementary-material"}A and S13B).Figure 3Retinal Thinning and Light Response Deficits in *Dhdds*^flx/flx^ iCre^+^Mice(A, left panel) Retinal thickness in *Dhdds*^flx/flx^ iCre^+^ and age-matched controls (n = 4/age group) was measured using SD-OCT. The panel provides representative SD-OCT images (including optic nerve head \[ONH\]) comparing *Dhdds*^flx/flx^ iCre^−^ controls with *Dhdds*^flx/flx^ iCre^+^ between PN 4 and 6 weeks (color code for experimental groups for all panels has been provided within the OCT panel). The ONL is demarcated by yellow dotted lines. (A, right panel) Graphical representation of the measured ONL thickness (in mm) in *Dhdds*^flx/flx^ iCre^+^ mice and age-matched controls. *Dhdds*^flx/flx^ iCre^+^ mice exhibit ONL thickness comparable to controls at PN 4 weeks and undergo significant thinning at PN 5 weeks (reduced by 50%) and PN 6 weeks (reduced by 80%--90%) (n = 4).(B, *top and middle panels*) Scotopic ERG responses in *Dhdds*^flx/flx^ iCre^+^ mice were markedly diminished at all time points tested, relative to age-matched *Dhdds*^flx/flx^ iCre^−^ controls (flash intensity range: 10^−4^ to 500 cd-s/m^2^). Both a- and b-wave amplitude maxima in response to flash stimuli were plotted as a function of flash intensity (top and middle panels, respectively). At very low flash intensities (10^−4^ cd-s/m^2^), pure rod response b-wave amplitudes were significantly reduced in all age groups. Both scotopic (rod-driven) a-wave and b-wave responses of PN 6-week-old *Dhdds*^flx/flx^ iCre^+^ mice were significantly decreased. (See [Figure S6](#mmc1){ref-type="supplementary-material"} for representative scotopic ERG traces at saturating flash intensity.) (B, *bottom panel*) Light-adapted, photopic (cone-driven) ERG responses of *Dhdds*^flx/flx^ iCre^+^ mice were comparable to those of controls at PN 4 and 5 weeks, despite reduced photopic responses at those time points. However, *Dhdds*^flx/flx^ iCre^+^ photopic ERG responses were minimal at PN 6 weeks and differences were statistically significant compared with age-matched controls.(C, *left panel*) Scotopic b:a wave magnitude ratios were significantly increased at all flash intensities ≥1.25 cd-s/m^2^ in PN 5-week-old *Dhdds*^flx/flx^ iCre^+^ mice, when compared with age-matched controls. (C, *right panel*) Scotopic b-wave implicit times were significantly lengthened in both PN 4- and 5-week-old *Dhdds*^flx/flx^ iCre^+^ mice, when compared with controls, for all flash intensities ≥0.4 cd-s/m^2^. (n = 12 for control; n = 9 for *Dhdds*^flx/flx^ iCre^+^ PN 4 weeks; n = 12 for *Dhdds*^flx/flx^ iCre^+^ PN 5 weeks; n = 7 for *Dhdds*^flx/flx^ iCre^+^ PN 6 weeks). ∗p \< 0.05, ∗∗p \< 0.01; Welch\'s (unpaired) t test.

Scotopic ERG responses in *Dhdds*^flx/flx^ iCre^+^ mice were diminished at all tested time points, relative to age-matched *Dhdds*^flx/flx^ iCre^−^ controls (n = 7--12/group/time point) ([Figure 3](#fig3){ref-type="fig"}B). Scotopic a- and b-waves were recorded using a customized 16-step regimen over a range of flash intensities spanning 10^−5^ to 500 cd-s/m^2^. The a-wave amplitude is a measure of PR hyperpolarization in response to photon flash stimulus. Scotopic a-wave amplitudes (at PN weeks 4, 5, and 6) were significantly lower, compared with those of age-matched controls, at all flash intensities ≥0.4 cd-s/m^2^. Scotopic a-wave amplitudes in *Dhdds*^flx/flx^ iCre^+^ mice at PN 4 weeks (n = 9) were significantly diminished at all flash intensities (∼75% of the maximal control response amplitude \[n = 12\]). At PN 5 weeks of age (n = 12), a time point at which significant thinning of the ONL was observed, a-wave response amplitudes were significantly diminished (∼35% of control values). The a-wave ERG responses in *Dhdds*^flx/flx^ iCre^+^ were essentially extinguished by PN 6 weeks of age (n = 7) ([Figure 3](#fig3){ref-type="fig"}B, upper panel). A similar time-dependent, significant decrease was observed in scotopic b-wave responses of *Dhdds*^flx/flx^ iCre^+^ mice, when compared with controls ([Figure 3](#fig3){ref-type="fig"}B, middle panel). Interestingly, b-wave response amplitudes were significantly reduced in all age groups of *Dhdds*^flx/flx^ iCre^+^ mice compared with age-matched controls (for all flash intensities ≥10^−3^ cd-s/m^2^), even at low flash intensities that may correspond to pure rod-mediated responses. Scotopic b-wave response amplitudes of *Dhdds*^flx/flx^ iCre^+^ mice at PN 6 weeks of age (n = 7) exhibited about a 7-fold decrease compared with controls. Representative scotopic ERG traces for *Dhdds*^flx/flx^ iCre^+^ mice and age-matched controls, at a saturating flash intensity of 500 cd-s/m^2^, are provided in [Figure S6](#mmc1){ref-type="supplementary-material"}. Under these conditions, whereas control responses were robust at all ages tested, the *Dhdds*^flx/flx^ iCre^+^ mice exhibited diminishing response amplitudes, being nearly extinguished by PN 6 weeks.

Scotopic b:a wave amplitude ratios were significantly increased at PN 5 weeks of age in *Dhdds*^flx/flx^ iCre^+^ mice at all flash intensities ≥0.4 cd-s/m^2^, compared with age-matched controls. However, at PN 4 weeks of age, *Dhdds*^flx/flx^ iCre^+^ mice showed increased scotopic b:a wave amplitude ratios only at flash intensities ≥150 cd-s/m^2^ ([Figure 3](#fig3){ref-type="fig"}C, left panel). Also, implicit time values for scotopic b-wave were significantly elevated at both PN 4 and 5 weeks of age in *Dhdds*^flx/flx^ iCre^+^ mice ([Figure 3](#fig3){ref-type="fig"}C, right panel), compared with age-matched controls.

In contrast, cone PR-driven (photopic) ERG responses (calculated as the difference between the photopic b-wave and a-wave maxima) in *Dhdds*^flx/flx^ iCre^+^ mice at PN 4 and 5 weeks were comparable with those of age-matched controls at all flash intensities (ranging from 10^−1^ to 30 cd-s/m^2^) ([Figure 3](#fig3){ref-type="fig"}B, bottom panel). However, photopic responses at PN 6 weeks of age were extinguished (n = 7) (i.e., equivalent to background noise levels), consistent with a rod-cone dystrophy (see [Discussion](#sec3){ref-type="sec"}).

Immunohistochemical (IHC) analysis of retinas from controls and *Dhdds*^flx/flx^ iCre^+^ mice at PN 5 weeks (a time point at which structural and functional deficits in the retina were observed) with antibodies against rod opsin and glial fibrillary acidic protein (GFAP) suggested several key degenerative features. The GFAP immunoreactivity pattern demonstrated gliosis of the degenerating *Dhdds*^flx/flx^ iCre^+^ retina (green channel, [Figure 4](#fig4){ref-type="fig"}B). GFAP decorates only astrocytes and the Müller glial "endfeet" (i.e., the so-called inner limiting membrane) in a representative control retina (*green* channel, [Figure 4](#fig4){ref-type="fig"}A). Anti-opsin immunohistochemistry (*red* channel, [Figure 4](#fig4){ref-type="fig"}B) revealed dramatic shortening of ROS in *Dhdds*^flx/flx^ iCre^+^ mice at PN 5 weeks, when compared with controls (*red* channel, [Figure 4](#fig4){ref-type="fig"}A), fully consistent with the ERG results (see earlier discussion).Figure 4Morphological and Degenerative Features of the Dhdds^flx/flx^ iCre^+^ Retina(A and B) Confocal micrographs of (A) *Dhdds*^flx/flx^ iCre^−^ and (B) *Dhdds*^flx/flx^ iCre^+^ mouse retinas at PN 5 weeks of age. Note the shortening of rod outer segments (detected using anti-opsin; *red* channel) in *Dhdds*^flx/flx^ iCre^+^ retina (B) and the accompanying gliosis (detected using anti-GFAP; *green* channel). GFAP labeling was limited to Műller glial endfeet and astrocytes (comprising the internal limiting membrane at the vitreoretinal interface) in controls (A). *Dhdds*^flx/flx^ iCre^+^ mice did not exhibit anti-opsin immunostaining in either the inner segments (IS) or the photoreceptor perinuclear space, suggesting unhindered opsin trafficking (scale bars, 20 μm).(C and D) Electron micrographs of *Dhdds*^flx/flx^ iCre^+^ outer retina at PN 5 weeks, indicating grossly shortened and poorly aligned, but otherwise ultrastructurally normal, outer segments (OS) (*blue arrows*, D) and functional RPE phagocytosis (*yellow arrow*, D). Note pyknotic nuclei (*blue arrowheads*, C) and thinning of ONL (6 nuclei in a row, *yellow bracket*, C). Scale bars: 10 μm in (C) and 500 nm in (D).(E) *Dhdds*^flx/flx^ iCre^−^ retina did not exhibit TUNEL labeling. Iba-1 immunoreactivity of microglial cell bodies and arbors was limited to few cell bodies in PN 4- to 5-week-old *Dhdds*^flx/flx^ iCre^−^ retina (see [Figure S8](#mmc1){ref-type="supplementary-material"}D) (scale bar: 20 μm).(F) Retinal dystrophy in *Dhdds*^flx/flx^ iCre^+^ mice was characterized by photoreceptor-specific autonomous cell death, as evidenced by TUNEL labeling (*white arrows*, 488-nm channel). Autonomous cell death in *Dhdds*^flx/flx^ iCre^+^ mice was accompanied by infiltration of Iba-1-positive microglia (*red* channel) into the ONL and subretinal space (*whitearrows*. Furthermore, we observed microglial phagocytosis of TUNEL-negative photoreceptors ("phagoptosis") leading to non-autonomous cell death (denoted by *asterisks*) (scale bar: 20 μm).(G) Western blot analysis and semi-quantitative densitometry indicates significant up-regulation of GFAP (marker of gliosis) and ICAM-1 (facilitates trans-endothelial migration of leukocytes and breakdown of the blood-retinal barrier). GLUL and ACTB served as loading controls for Müller glia and total protein, respectively. (H) Quantification of GFAP levels in *Dhdds*^flx/flx^ iCre^−^ (*black*) vs. *Dhdds*^flx/flx^ iCre^+^ (*gray*) mouse retinas on Western blots (see G), normalized to ACTB. (I) Quantification of ICAM1 levels in *Dhdds*^flx/flx^ iCre^−^ (*black*) vs. *Dhdds*^flx/flx^ iCre^+^ (*gray*) mouse retinas on Western blots (see G), normalized to ACTB. ∗p \< 0.05, ∗∗p \< 0.01; Welch\'s (unpaired) t test.

Defective trafficking ("mislocalization") of opsin has been observed in animal models using either tunicamycin-induced or genetic inhibition of global proteome glycosylation ([@bib53], [@bib23], [@bib24], [@bib26]). However, in the *Dhdds*^flx/flx^ iCre^+^ retina at an intermediate degenerative stage (PN 5 weeks), we did not observe such defects, e.g., inner segment/cytoplasmic accumulation of opsin, plasma membrane localization along the inner segment, and even to the synaptic terminal. Despite shortening of ROS, opsin trafficking was comparable to that of age-matched control ([Figures 4](#fig4){ref-type="fig"}A and 4B). We utilized an established murine model of autosomal dominate RP (adRP)---the *Nog*^Rho−/-^ mouse, harboring mutations of the two N-terminal asparagine residues, N2 and N15---to demonstrate the trafficking fate of opsin in an animal model of true opsin hypoglycosylation. IHC revealed opsin accumulation in the inner segment, perinuclear space, as well as synapses of *Nog*^Rho−/-^ retinas (*white arrows*, [Figure S7](#mmc1){ref-type="supplementary-material"}). Furthermore, low- and high-magnification electron micrographs ([Figures 4](#fig4){ref-type="fig"}C and 4D, respectively) of *Dhdds*^flx/flx^ iCre^+^ retinas also suggested thinning of the ONL (*yellow bracket*, [Figure 4](#fig4){ref-type="fig"}C) and disorganized ROS (*blue arrows*, [Figure 4](#fig4){ref-type="fig"}D), but with normal lamellar disk membrane ultrastructure ([Figure 4](#fig4){ref-type="fig"}D). Surprisingly, despite the rod-specific and essentially quantitative ablation of *Dhdds*, these observations are not comparable with pathological features in models of opsin glycosylation defects.

We evaluated whether the rapid thinning of the outer retina was due exclusively to rod cell death, owing to the rod-specific deletion of *Dhdds*. For this purpose, formaldehyde-fixed, paraffin-embedded sections of eyes from *Dhdds*^flx/flx^ iCre^+^ and control mice (at PN 5 weeks, a time point at which the retina is in an intermediate stage of degeneration) were subjected to TUNEL analysis. Confocal fluorescence microscopy revealed TUNEL labeling (*green* channel) exclusively in the ONL of the *Dhdds*^flx/flx^ iCre^+^ retina ([Figure 4](#fig4){ref-type="fig"}F; *white arrows*, [Figures S8](#mmc1){ref-type="supplementary-material"}A--S8C); the labeling pattern was consistent with that expected for rod (not cone) PRs. Control retinas did not exhibit TUNEL-positive labeling, as expected ([Figure 4](#fig4){ref-type="fig"}E). These data are consistent with the ERG data described earlier in the discussion, suggesting a role for autonomous rod PR cell death in the observed ONL thinning.

We further observed that PR cell death was accompanied by phagocytosis of *live*, TUNEL-*negative* neurons by activated microglia, as has been reported for other models of retinal degeneration ([@bib85]). IHC analysis using antibodies to Iba-1 (a faithful marker of microglia) in *Dhdds*^flx/flx^ iCre^+^ mice revealed infiltration of activated microglia into the ONL (*asterisk*, [Figure 4](#fig4){ref-type="fig"}H) as well as the subretinal space (i.e., the zone normally occupied by PR outer segments) (*arrows*, [Figures 4](#fig4){ref-type="fig"}H and [S9](#mmc1){ref-type="supplementary-material"}A--S9C). By contrast, age-matched control retinas showed horizontally ramified microglia in the inner retinal layers only, as expected ([Figures 4](#fig4){ref-type="fig"}G and [S8](#mmc1){ref-type="supplementary-material"}D). Representative high-magnification confocal microscopic images of activated microglia with phagocytic cups engulfing PR soma were observed (*red* arrows, [Figure S8](#mmc1){ref-type="supplementary-material"}F). Activated microglia/macrophages in the subretinal space were quantified (utilizing hematoxylin and eosin \[H&E\] staining) as the number of nuclei in the typically acellular subretinal space (n = 3 sections of 10 μm thickness per animal, n = 8/group) (*black arrows*, [Figures S8](#mmc1){ref-type="supplementary-material"}A and S8B). *Dhdds*^flx/flx^ iCre^+^ mice exhibited a 4-fold increase in the number of nuclei in the subretinal space, when compared with the same region of the retina in age-matched controls (nuclei in the subretinal space were observed only in peripheral retina of WT mice). This was further observed as DAPI-positive, Iba-1-positive cells (interpreted as microglia/macrophages) in the subretinal space (*white arrowheads*, [Figures 4](#fig4){ref-type="fig"}F, [S8](#mmc1){ref-type="supplementary-material"}E, [S9](#mmc1){ref-type="supplementary-material"}A, and S9B)

Because Iba-1 immunoreactivity is indicative of an endogenous immune response, we adopted an unbiased ("shotgun") cytokine screening approach to reveal other molecular players in the observed retinal degeneration. Surprisingly, the only two prominent targets with significant change (\>2-fold increase) that emerged in *Dhdds*^flx/flx^ iCre^+^ retinas, when compared with age-matched controls, were ICAM-1 and CXCL-10. Cytokine array data along with quantification are provided in [Figure S10](#mmc1){ref-type="supplementary-material"}. Up-regulation of ICAM-1 and GFAP in *Dhdds*^flx/flx^ iCre^+^ retinas (n = 3/group) was further validated by western blot analysis and semi-quantitative densitometry. Whole retinal ICAM-1 and GFAP levels were approximately 8- and 4-fold higher (n = 3/group), respectively, in *Dhdds*^flx/flx^ iCre^+^ retinas compared with age-matched controls ([Figures 4](#fig4){ref-type="fig"}G--4I). Glutamine synthetase (GLUL) and β-actin (ACTB) served as loading controls for Műller glia and total retinal protein, respectively ([Figure 4](#fig4){ref-type="fig"}G).

Protein N-glycosylation Is Active in the Dhdds^flx/flx^ iCre^+^ Retina {#sec2.3}
----------------------------------------------------------------------

We investigated the glycosylation status of proteins in PN 5-week-old *Dhdds*^flx/flx^ iCre^+^ retinas compared with retinas from age-matched *Dhdds*^flx/flx^ iCre^−^ mice (which served as controls, instead of WT mice). This was achieved by adopting a dual-lectin staining strategy that exhibits differential binding of lectins to rod versus cone PRs: Concanavalin-A (Con-A, a lectin with specific affinity for non-reducing α-D-mannosyl and α-D-glucosyl residues and which binds to the interphotoreceptor rod matrix sheath) and peanut agglutinin (PNA, a lectin that preferentially binds to galactosyl-β(1,3)-N-acetylgalactosamine, a constituent of the interphotoreceptor cone matrix sheath) ([@bib75], [@bib30]). If *Dhdds* ablation inhibited *N*-glycosylation as hypothesized, we expected to observe a lack of Con-A binding to rod PRs. Surprisingly, Con-A labeling of the rod-rich outer retinal layer of *Dhdds*^flx/flx^ iCre^+^ mice at PN 5 weeks was robust (including ROS, ONL, and outer plexiform layer \[OPL\]), comparable to age-matched controls (*green* channel, [Figures 5](#fig5){ref-type="fig"}A and 5B). PNA staining (*far-red* channel, pseudocolored *magenta*) suggested that cone PR density and distribution in rod-*Dhdds*-null mice was not altered at PN 5 weeks ([Figures 5](#fig5){ref-type="fig"}A--5D). PNGase-F-treated sections subsequently subjected to dual lectin staining were utilized as true "negative" controls ([Figures 5](#fig5){ref-type="fig"}C and 5D), as PNGase-F treatment should remove all N-linked glycans and, hence, abolish Con-A binding. Similar to Con-A labeling, wheat germ agglutinin (which detects N-acetyl-D-glucosamine residues) also exhibited robust binding to *Dhdds*^flx/flx^ iCre^+^ retinas, comparable to that of controls ([Figure S11](#mmc1){ref-type="supplementary-material"}).Figure 5Protein *N*-Glycosylation is Functional in the *Dhdds*^flx/flx^ iCre^+^ Retina(A--F) The glycosylation status of *Dhdds*^flx/flx^ iCre^+^ retinas (PN 5 weeks) was evaluated and compared with that of controls using a dual-lectin cytochemical staining strategy (Concanavalin-A \[Con-A\] in *green* channel, and cone PR-specific peanut agglutinin \[PNA\] in *far-red* \[pseudocolored *magenta*\] channel). Confocal fluorescence micrographs demonstrate robust Con-A labeling in *Dhdds*^flx/flx^ iCre^+^ retina (B) comparable to that in controls (A), suggesting normal protein *N*-glycosylation in *Dhdds*^flx/flx^ iCre^+^ mouse retinas. This was validated by testing the PNGase-F sensitivity of Con-A binding. Both control and *Dhdds*^flx/flx^ iCre^+^ retinas (C and D, respectively) were sensitive to PNGase-F activity and exhibited markedly reduced Con-A binding. Furthermore, cone density and distribution (as indicated by PNA binding) was comparable in both control and *Dhdds*^flx/flx^ iCre^+^ retinas. PNA labeling was unaffected by PNGase-F treatment, because PNGase-F does not cleave the cognate disaccharide Gal-β(1,3)-GalNAc to which PNA binds. Scale bars: 20 μm in (A--D). Retinal protein extracts from *Dhdds*^flx/flx^ iCre^+^ and control mice (n = 3/group, at PN 5 weeks) were subjected to PNGase-F treatment, and western blot analysis was performed, probing the blot with antibodies to opsin (RHO) and LAMP2 (E and F, respectively). Untreated protein extracts served as negative controls for PNGase-F treatment. Opsin and LAMP2 proteins from *Dhdds*^flx/flx^ iCre^+^ retinas exhibited PNGase-F sensitivity, and a subsequent M~r~ mobility shift (from ∼37 to ∼35 kDa, and from ∼120 to ∼40 kDa, respectively) as a consequence of cleaving their *N*-linked glycans, relative to the lanes containing untreated retinal extracts. This same behavior was observed when retinal extracts from control mice were subjected to PNGase-F treatment. Hence, RHO and LAMP2 were *N*-glycosylated in *Dhdds*^flx/flx^ iCre^+^ mice. Note the decreased levels of opsin in lanes corresponding to *Dhdds*^flx/flx^ iCre^+^, when compared with controls.

We further verified protein *N*-glycosylation in *Dhdds*^flx/flx^ iCre^+^ retinas by examining PNGase-F sensitivity of opsin (the most abundant rod PR-specific glycoprotein) and LAMP2 (lysosome-associated membrane glycoprotein). Opsin and LAMP2 western blot analysis of PNGase F-treated versus untreated retinal protein extracts from *Dhdds*^flx/flx^ iCre^+^ and control mice at PN 5 weeks was consistent with the lectin cytochemical staining results described earlier in the article. Both opsin and LAMP2 from *Dhdds*^flx/flx^ iCre^+^ retinas ([Figures 5](#fig5){ref-type="fig"}E and 5F) were sensitive to PNGase-F treatment, and exhibited mobility shifts relative to the untreated specimens (biological triplicates), as expected. These findings were comparable to those obtained with PNGase-F-treated versus untreated control retinas ([Figures 5](#fig5){ref-type="fig"}E and 5F).

Retinal Dolichol Levels Are Markedly Reduced in Dhdds^flx/flx^ iCre^+^ Mice {#sec2.4}
---------------------------------------------------------------------------

Age-dependent reduction of PR number in *Dhdds*^flx/flx^ iCre^+^ retinas ([Figures 3](#fig3){ref-type="fig"}A and 3B) presents a challenge in delineating the expected decrease in total dolichol content due to ablation of *Dhdds*, as opposed to the decrease in the PR population (cell mass). Therefore, we utilized retinas from PN 4-week-old *Dhdds*^flx/flx^ iCre^−^ and *Dhdds*^flx/flx^ iCre^+^ mice to measure whole retinal dolichol content---a time point at which no significant attrition in PR mass was observed ([Figures 3](#fig3){ref-type="fig"}A and 3B). For mass spectrometry quantification of dolichol, five retinas were pooled per sample to obtain sufficient tissue mass (n = 3 for *Dhdds*^flx/flx^ iCre^−^ mice, n = 4 for *Dhdds*^flx/flx^ iCre^+^ mice). Liquid chromatography-mass spectrometry (LC-MS) analysis was performed to quantify the two dominant dolichol species---C90 (Dol-18) and C95 (Dol-19) (denoting dolichol species with 18 or 19 isoprene units and containing 90 or 95 carbon atoms, respectively); the sum of C90 plus C95 species was taken to represent the total retinal dolichol content. As shown in [Figure 6](#fig6){ref-type="fig"} (*top panel*, [Figure 6](#fig6){ref-type="fig"}A), retinas from *Dhdds*^flx/flx^ iCre^+^ mice exhibited about a 50% reduction (p \< 0.01) in total dolichol content, relative to *Dhdds*^flx/flx^ iCre^−^ (control) retinas. Despite this, the distribution of dolichol species remained unaltered: no significant difference was observed in the ratio of Dol-18 to Dol-19 (*bottom* panel, [Figure 6](#fig6){ref-type="fig"}A). Representative mass spectra of C90 and C95 dolichols from *Dhdds*^flx/flx^ iCre^+^ retinas are shown in [Figure 6](#fig6){ref-type="fig"}B.Figure 6Dolichol Content Is Markedly Decreased in *Dhdds*^flx/flx^ iCre^+^ Retinas, Relative to Age-Matched Controls(A) LC-MS analysis of dolichols extracted from *Dhdds*^flx/flx^ iCre^+^ and control retinas demonstrated ∼50% decrease in the total dolichol content of *Dhdds*^flx/flx^ iCre^+^ retinas (n = 4), when compared with controls (n = 3) (*upper panel*, A). However, there was no selectivity as a function of dolichol chain lengths: the Dol-18:Dol-19 ratio \[C90:C95\] in *Dhdds*^flx/flx^ iCre^+^ retinas was comparable to that of age-matched controls (*lower panel*, A).(B) Mass spectra of Dol-18 and Dol-19 species from *Dhdds*^flx/flx^ iCre^−^ (control) and *Dhdds*^flx/flx^ iCre^+^ retinas. Note that signals of ammoniated \[M + NH~4~\]^+^ and sodiated \[M + Na\]^+^ forms of respective Dol isotopologues are clearly visible. Each sample analyzed was prepared by pooling five retinas from the respective genotype group. ∗p \< 0.05; Welch\'s (unpaired) t test.

Discussion {#sec3}
==========

Several *in vivo* biochemical, pharmacological, and genetic studies ([@bib24], [@bib26], [@bib39], [@bib23], [@bib53]) have demonstrated retinal *de novo* synthesis of dolichol and the requirement of dolichol-dependent *N*-glycosylation in maintaining the normal structure and function of the retina, particularly as regards the intracellular trafficking and incorporation of opsin, the predominant PR-specific glycoprotein, into ROS membranes. Recent whole-exome sequencing studies have revealed the RP59-causative missense mutations in the gene coding for DHDDS, which catalyzes the committed step of the mevalonate pathway directed toward dolichol synthesis ([@bib84], [@bib87]). The present study is the first to employ a genetic approach, using conditional deletion of DHDDS in retinal rod PRs, to study the effects of altered PR dolichol homeostasis, as a tractable step toward understanding the pathological mechanisms underlying RP59. The following discussion provides broad insights into the challenges in modeling a complex metabolic disorder pertaining to dolichol homeostasis and compares the findings of this study (i.e., rapid structural and functional degeneration of PRs and markedly decreased dolichol content, but *without* any obvious impact on protein N-glycosylation), using a murine model, with the human RP59 disease.

Important Considerations in Generation and Verification of Rod PR-Specific Dhdds Knockout Mice {#sec3.1}
----------------------------------------------------------------------------------------------

Multiple rod PR-specific, Cre recombinase-expressing mouse lines (driven by rod PR-specific Nrl,/LMOP/RHO promoters) may be utilized for the targeted excision of the loxP-modified gene of interest selectively in rod cells ([@bib6], [@bib46], [@bib47]). We set out to compare the spatiotemporal expression/activity of Cre recombinase in two Cre lines (LMOP-Cre and Rho-iCre75), utilizing the ZsGreen reporter strategy ([Figures 2](#fig2){ref-type="fig"}D,[S3](#mmc1){ref-type="supplementary-material"}, and [S5](#mmc1){ref-type="supplementary-material"}). The Rho-iCre75 mouse line exhibited Cre recombinase activity in almost all terminally differentiated rod PRs ([Figure S5](#mmc1){ref-type="supplementary-material"} and [2](#fig2){ref-type="fig"}D), in good agreement with the original report describing the Rho-iCre75 mouse line ([@bib47]), whereas the LMOP-Cre line exhibited mosaic Cre-recombinase activity (ZsGreen reporter expression in ∼30%--40% of rod PRs only at PN 90 days) ([Figure S12](#mmc1){ref-type="supplementary-material"}). Therefore, we utilized the Rho-iCre75 line to generate the *Dhdds*^flx/flx^ iCre^+^ model, which successfully induced *Dhdds* deletion in terminally differentiated rod PRs. Importantly, Cre expression in the Rho-iCre75 line commences at around PN day 7; at that stage of retinal development, rod cell fate has been determined, but initiation of ROS assembly has just barely commenced and full maturation of rods has yet to be achieved.

Tail snip genotyping does not provide direct evidence for exon excision in the target tissue/cell type. Owing to the lack of availability of reliable antibodies against murine DHDDS, it is challenging to directly verify DHDDS protein levels, or cell type-specific knockout of the target. Therefore, we verified the establishment of this model by multiple approaches: (1) indirect tail snip genotype analysis ([Figure S4](#mmc1){ref-type="supplementary-material"}), (2) direct retinal genotyping (testing whole tissue genomic DNA extract for *Dhdds* excision, [Figure 2](#fig2){ref-type="fig"}C), (3) the ZsGreen reporter mouse approach to detect Cre-recombinase activity ([Figure 2](#fig2){ref-type="fig"}D), and (4) ISH ([Figures 2](#fig2){ref-type="fig"}E and 2F) to obtain histology-level verification of cell type-specific *Dhdds* ablation. PCR assay involving whole retinal genetic material utilized a short extension period to only select for the 584-bp intronic PCR product (upon exon excision). One would predict that using a long extension period would amplify the long, non-excised *Dhdds* allele arising from other retinal cell types and may not distinguish heterozygous from homozygous knockouts. Therefore, retinal genotyping, when preceded by preliminary tail snip analysis (to confirm *loxP* homozygosity), and the reporter mouse strategy may provide better qualitative evidence for target excision. ISH using an RNA-based technology (BaseScope; ACD Bio) to probe control and *Dhdds*^flx/flx^ iCre^+^ retinas ([Figures 2](#fig2){ref-type="fig"}E and 2F) provided important morphological and physiological context regarding *Dhdds* expression in the retina, as well as direct verification of successful *Dhdds* excision in a cell type-specific manner. Importantly, ISH labeling of the adjacent INL provides an on-section internal positive control for validating *Dhdds* mRNA detection by the BaseScope ZZ probes.

DHDDS belongs to the superfamily of CPT enzymes involved in the synthesis of long-chain polyisoprenoid products upon *cis*-condensation of FPP and IPP (yielding ≥ C~55~ long-chain products). Structural elucidation of *E*. *coli* undecaprenyl pyrophosphate synthase (UPPS) has revealed critical amino acids involved in hydrogen bonding and hydropathic interactions with FPP and IPP ([@bib29]). Multiple sequence analysis using CLUSTALW2 algorithm suggests that these critical amino acids are well conserved in murine DHDDS CPT and other mammalian CPT enzymes (compare [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}) ([@bib44]). Targeted ablation of coding exon 3 of *Dhdds* is predicted to render the enzyme fully inactive due to the loss of the amino acids required for hydropathic interaction with FPP and hydrogen bonding with the phosphate groups of IPP ([Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}). Furthermore, compensatory mechanisms for dolichol synthesis can be ruled out due to the absence of DHDDS homologs.

Whole-exome sequencing of patients with RP59 revealed point mutations in the DHDDS gene, the predominant mutation being K42E. The K42E mutation renders the human DHDDS gene product *hypoactive*, unlike the mouse rod-specific *Dhdds* exon 3 knockout (with expected total loss of function of DHDDS activity) ([Figure S2](#mmc1){ref-type="supplementary-material"}). Another reported pathogenic DHDDS mutation is W64X (phenylalanine to STOP codon), which resulted in early postnatal lethality ([@bib62]). This clinically "severe" mutation generates a fully dysfunctional gene product comparable to the loss of the DHDDS catalytic activity in the *Dhdds*^flx/flx^ iCre^+^ mouse model. The *Dhdds*^flx/flx^ iCre^+^ mouse model differs from the human RP59 disease in at least two respects: (1) the RP59-causing DHDDS mutations (see [Figure S3](#mmc1){ref-type="supplementary-material"}) globally affect all tissues and cell types, including the retina, whereas our mouse knockout model employs targeted *Dhdds* ablation only in rod PRs and (2) the predominant RP59 point mutation, K42E, is only hypomorphic, whereas our knockout model is a total loss-of-function insult, although cell type specific. Despite these differences, the findings in this study suggest that conditional deletion of *Dhdds* in rod PRs is sufficient to elicit a profound and rapid retinal degeneration. Furthermore, the *Dhdds*^flx/flx^ iCre^+^ mouse line serves as a reliable biochemical model (owing to the presumed complete loss of DHDDS activity) to investigate the rod PR requirement for the dolichol pathway ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Structural, Functional, and Pathological Consequences of Rod Photoreceptor-Specific Dhdds Deletion {#sec3.2}
--------------------------------------------------------------------------------------------------

The current study was aimed at investigating the PR-specific disease mechanism(s) of RP59. *In vivo* retinal imaging (SD-OCT analysis, [Figure 3](#fig3){ref-type="fig"}A) suggested that ONL thickness in *Dhdds*^flx/flx^ iCre^+^ mice was comparable to that of age-matched controls at PN 4 weeks. Surprisingly, the unaltered structural integrity at PN 4 weeks in *Dhdds*^flx/flx^ iCre^+^ retinas did not correspond to full *functional* integrity (see [Figures 3](#fig3){ref-type="fig"}B, and [S6](#mmc1){ref-type="supplementary-material"}): scotopic ERG responses (a- and b-waves) at all flash intensities (10^−4^ to 500 cd-s/m^2^) were significantly lower compared with those of age-matched (PN 4 weeks) controls. *Dhdds*^flx/flx^ iCre^+^ retinas exhibited both profound structural and functional deficits at PN 5 and 6 weeks. ONL thickness was significantly reduced at PN 5 weeks (by ∼50% \[p \< 0.05\], compared with age-matched WT C57BL/6J controls, [Figure 3](#fig3){ref-type="fig"}B). Low-magnification images of H&E-stained sections of eyes from PN 5-week-old *Dhdds*^flx/flx^ iCre^+^ mice showed PR thinning ([Figures S13](#mmc1){ref-type="supplementary-material"}B and S13D) compared with age-matched controls ([Figures S13](#mmc1){ref-type="supplementary-material"}A and S13C). The rapid PR loss observed in *Dhdds*^flx/flx^ iCre^+^ mice can be attributed to the following two degenerative processes: (1) autonomous rod PR-specific cell death, as observed by TUNEL labeling, and (2) phagocytosis of live PRs by activated, Iba-1-positive microglia ([Figures 4](#fig4){ref-type="fig"}F, [S8](#mmc1){ref-type="supplementary-material"}E, S8F, and [S9](#mmc1){ref-type="supplementary-material"}), leading to *non*-autonomous loss of PRs. The exact details of rod PR-autonomous defective cell processes leading to cell death upon *Dhdds* deletion remain to be elucidated. The *Dhdds*^flx/flx^ iCre^+^ mice also exhibited activated microglia in the subretinal space, i.e., between the outer neural retina and the underlying retinal pigment epithelium ([Figures 4](#fig4){ref-type="fig"}F, [S8](#mmc1){ref-type="supplementary-material"}E, S8F, and [S9](#mmc1){ref-type="supplementary-material"}), which is normally "virtual" space filled with PR outer segments and associate extracellular matrix constituents. By contrast, the microglial population in retinas of young, age-matched control mice was notably sparse, and restricted to just the inner retinal layers (nner plexiform layer \[IPL\], ganglion cell layer \[GCL\]), as judged by Iba-1 immunostaining ([Figures 4](#fig4){ref-type="fig"}E and [S8](#mmc1){ref-type="supplementary-material"}D). Although previous investigators have made similar observations regarding the distribution of microglia in the normal C57BL/6 mouse retina ([@bib83], [@bib36], [@bib13]), often the Iba-1-positive cells were more numerous than what we observed in the present study. The reasons for these differences are not fully apparent, but could be due to age-dependent population differences (e.g., prior studies tended to use older mice than those employed here), or possibly to differences in the type of embedment media used (i.e., optimal cutting temperature embedment medium \[O.C.T.\] frozen sections versus paraffin sections) ([@bib3], [@bib55]). Proteomic and/or transcriptomic approaches offer potentially fruitful avenues to investigate the downstream cellular and molecular processes that are altered upon *Dhdds*-dependent inhibition of dolichol synthesis. Pharmacological inhibition of microglial activity in the retina also may provide a therapeutic avenue for preventing the rapid retinal degeneration observed in the *Dhdds*^flx/flx^ iCre^+^ mouse model. Our cytokine array analysis (and correlative western blot analysis) revealed \>8-fold up-regulation of ICAM-1 levels in *Dhdds*^flx/flx^ iCre^+^ retinas compared with age-matched controls; such has been implicated in leukocyte adhesion, as well as breakdown in the blood-retinal barrier ([@bib80], [@bib18], [@bib50]). The presumed involvement of ICAM-1 in microglial recruitment and in the observed retinal degeneration in this animal model also remains to be investigated further. Another key degenerative feature of the *Dhdds*^flx/flx^ iCre^+^ retina is gliosis, as evidenced by significant up-regulation of GFAP relative to that of the Müller glial marker glutamine synthetase ([Figures 4](#fig4){ref-type="fig"}B and 4G--4I).

The SD-OCT results (i.e., ONL thinning) demonstrated rapid retinal degeneration in *Dhdds*^flx/flx^ iCre^+^ mice; however, whereas most of that loss reasonably could be attributed to rod cell degeneration and demise (given that rods account for ∼97% of the PRs in the mouse retina; [@bib12]), the involvement of cone degeneration and demise cannot be discounted. Cone function was directly assessed utilizing photopic ERG analysis at all tested time points (PN 4, 5, and 6 weeks) ([Figure 3](#fig3){ref-type="fig"}B, bottom panel). Electrophysiological responses of cone PRs were unaltered and robust until massive rod dropout was observed at PN 6 weeks ([Figure 3](#fig3){ref-type="fig"}B, bottom panel), suggesting a rapid rod-cone dystrophy. The rod-cone dystrophy observed in this animal model, although consistent with the rod-cone dystrophy observed in patients with RP59 ([@bib41]), should be interpreted with caution. The rod-cone dystrophy observed in the *Dhdds*^flx/flx^ iCre^+^ mouse model is "by design," i.e., rod PR primary cell death is attributable to the rod-targeted excision of *Dhdds*, whereas cone PRs exhibit secondary dysfunction (i.e., a "bystander effect"; [@bib60], [@bib15], [@bib48]), which is independent of *Dhdds* activity. Cone-specific PNA staining, as expected, did not reflect any significant cone PR dropout even at PN 5 weeks ([Figures 5](#fig5){ref-type="fig"}C and 5D). The density and distribution of PNA-positive structures in *Dhdds*^flx/flx^ iCre^+^ mouse retinas appeared qualitatively comparable to that of age-matched controls, in agreement with the photopic ERG responses observed at PN 5 weeks ([Figure 4](#fig4){ref-type="fig"}C). PNA binds to *O-*linked glycans (specifically, the disaccharide Gal-β(1--3)-GalNAc), and therefore its binding to cone PRs is unaltered by PNGase-F treatment. We further documented cone arrestin distribution in PN 5-week-old *Dhdds*^flx/flx^ iCre^+^ retinas, compared with age-matched controls. We observed cone arrestin-positive structures both in the inner/outer segment region and in the OPL (PR synapses) ([Figures S13](#mmc1){ref-type="supplementary-material"}C and S13D).

Furthermore, we observed age-dependent increase in the scotopic b:a wave ratio ([Figure 3](#fig3){ref-type="fig"}C, left panel), in accordance with severe reductions in scotopic a-wave amplitudes, in relation to the reduction in b-wave amplitude. A similar increase in b:a wave ratio has been described in patients with PMM2-CDG ([@bib71]). However, we observe a significant decrease in both scotopic b-wave and a-wave amplitudes in the *Dhdds*^flx/flx^ iCre^+^ mice. Given that the *Dhdds* excision occurs exclusively in rod PRs, we interpret the increase in b:a wave ratio to be due to a significant and specific decrease in the a-wave component of the ERG. In addition, implicit times for *Dhdds*^flx/flx^ iCre^+^ mice were significantly longer compared with those of controls ([Figure 3](#fig3){ref-type="fig"}C, right panel). This finding along with the ERG amplitude analysis at all flash intensities clearly suggest less robust and more sluggish scotopic response in *Dhdds*^flx/flx^ iCre^+^ mice compared with age-matched controls. The increased b:a wave ratio in the conditional *Dhdds*^flx/flx^ iCre^+^ mouse model may not be directly suggestive of similar trends in patients carrying *systemic* DHDDS point mutations; however, a:b wave ratios have not been characterized, to date, in the DHDDS-CDG patient population.

In summary, the key features of this novel *Dhdds*^flx/flx^ iCre^+^ model include progressive ROS shortening, gliosis, PR cell death, and microglial activation, microglial migration to ONL and subretinal space, and phagoptosis of entire PR cells, leading to rapid rod-cone dystrophy by PN 5--6 weeks ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}). The findings in this model (characterized by presumed total loss of DHDDS CPT activity) may be important in ultimately understanding the underlying mechanisms involved in RP59 (caused by homozygous point mutations with mildly hindered CPT activity). Parallel efforts to this work in our laboratories currently involve generation of DHDDS dual point mutant knock-in mice harboring both K42E and T206A mutations, to create a potentially more representative model of RP59 (unpublished studies). Surprisingly, the K42E homozygous knock-in model (even up to PN 1 year of age) does not replicate the structural or functional deficit features observed either in patients with RP59 or in the *Dhdds*^flx/flx^ iCre^+^ model reported here, with the exception of marked gliosis ([@bib59]).

Biochemical Features of the Degenerating Dhdds^flx/flx^ iCre^+^ Retina {#sec3.3}
----------------------------------------------------------------------

We originally predicted that rod-specific *Dhdds* ablation would cause defective protein *N*-glycosylation in rods because of the biochemical requirement of protein glycosylation for Dol-P (see [Figure 1](#fig1){ref-type="fig"}) ([@bib17], [@bib7], [@bib38], [@bib39], [@bib40], [@bib4]). We first verified excision of *Dhdds* exon 3 in terminally differentiated rod PRs ([Figures S5](#mmc1){ref-type="supplementary-material"} and [Figure 2](#fig2){ref-type="fig"}) and utilized this model to analyze dolichol content and *N*-glycosylation status. However, contrary to our initial expectations, the observed rapid PR degeneration was *not* accompanied by a glycosylation defect ([Figures 5](#fig5){ref-type="fig"} and [S11](#mmc1){ref-type="supplementary-material"}). *In vitro* and *in vivo* studies involving deletion of genes encoding enzymes involved in dolichol synthesis have utilized different model systems, different genes of interest, various gene editing techniques, and different time points during cell growth/tissue differentiation. A study utilizing global ablation of *Dhdds* at the one-cell embryo stage in zebrafish, which has a cone-rich retina (unlike mouse), indicated defective protein glycosylation in the PRs, as evidenced by lack of cone PR-specific PNA staining ([@bib87]). Mouse embryonic/conditional ablation of *NUS1*, the gene encoding NgBR, the dimeric partner of the gene product of *Dhdd*s, causes embryonic lethality before E6.5, as well as loss of *N*-glycosylation ([@bib58], [@bib57]). However, curiously, biological samples (blood, urine, and fibroblasts) from patients with RP59 have been reported to exhibit a shift toward shorter dolichol chain length (increased Dol-18:Dol-19 mole ratios), without any appreciable hypoglycosylation defects ([@bib78], [@bib43]). Furthermore, *DHDDS* knockdown experiments in fully confluent cell culture models did not lead to an observable glycosylation defect ([@bib62]). One possible explanation for the divergent observations across various models may involve elevated dolichol synthesis during tissue development and the unusual biological stability (long half-life) of dolichol, particularly in neural tissue. The rate of dolichol synthesis and accumulation is highest during cell growth and tissue development ([@bib63], [@bib81], [@bib11], [@bib76], [@bib1], [@bib20], [@bib45]). Furthermore, dolichols are biologically very stable lipids with long half-lives, and the only known forms of dolichols are the free alcohol, phosphorylated derivatives, and esters of carboxylic acids ([@bib14], [@bib56]). Oxidative catabolism of dolichol, although postulated, has not yet been fully documented *in vivo* ([@bib70]). It should be noted that the control and *Dhdds*^flx/flx^ iCre^+^ mice utilized in this study were on a C57BL/6J background, and this study did not directly test the potential effects of other modifier mutations on the severity of the phenotype. However, we posit that the *Dhdds* K42E point knock-in mouse model may provide a better avenue to investigate the effects of genetic background on the RP59 phenotype ([@bib79], [@bib66], [@bib59]). LC-MS analysis of whole retinal dolichol content suggests ∼50% reduction upon RhoiCre-mediated deletion of *Dhdds* in rod PRs (see [Figures 2](#fig2){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Retinal dolichol content in our *Dhdds*^flx/flx^ iCre^+^ model was significantly reduced, whereas the Dol-18/Dol-19 ratio was unaltered, unlike observations as mentioned earlier regarding tissues and fluids obtained from patients with RP59 ([@bib78]) (see [Figure 6](#fig6){ref-type="fig"}). Reduction in whole retinal dolichol levels can be reasonably attributed to PR-specific loss of *Dhdds*. However, this finding may not account for any residual dolichol in PRs that may have been synthesized before Rho-iCre-mediated deletion of *Dhdds* had taken place in rod PRs ([Figures 2](#fig2){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}). Future investigations into the role of mammalian DHDDS and its heterodimeric partner, NgBR, during PR genesis and retinal development may more fully explain the "hypoglycosylation-free" phenotype observed in the *Dhdds*^flx/flx^ iCre^+^ mouse model described in this study (see [Figures 5](#fig5){ref-type="fig"} and [S10](#mmc1){ref-type="supplementary-material"}), as well as provide a deeper understanding of dolichol synthesis and homeostasis in retinal PRs. In addition, studying the effects of PR-specific *Dhdds* deletion on other important glycan modifications of proteins, such as *O-*mannosylation, may provide additional clues regarding the underlying mechanism driving RP59 pathology.

Inhibition of *N*-linked glycosylation perturbs vectorial trafficking of opsin and other ROS-destined proteins in PR cells and consequently compromises the inability to form PR outer segments ([@bib24], [@bib26], [@bib23], [@bib73], [@bib16], [@bib68]). However, surprisingly, although we observed shortening of ROS, we did not observe mislocalization of opsin, e.g., aberrant accumulation in the inner segment or in the perinuclear space of the ONL (see [Figures 5](#fig5){ref-type="fig"}A and 5B). In fact, we observed successful outer segment formation (see [Figures 4](#fig4){ref-type="fig"}C and 4D). Thus, our observations (see [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}) would argue *against* defective *N*-glycosylation upon Rho-iCre-mediated *Dhdds* excision, where Rho-iCre recombinase is expressed (starting at PN 7 days) *after* cell fate commitment to rod PR terminal differentiation ([@bib47]). However, the PR-specific ablation of *Dhdds* is sufficient to elicit primary degeneration of PRs, suggesting the requirement of continued endogenous dolichol synthesis in terminally differentiated rod PRs.

Limitations of the Study {#sec3.4}
------------------------

RP59 is an autosomal recessive, non-syndromic form of RP, caused by mutations in DHDDS ([@bib84], [@bib87]). Hence, although all cells require dolichol derivatives to carry out protein *N*-glycosylation, only the retina seems to be negatively impacted by such mutations in this disease. The present study was aimed at neither addressing the question of why RP59 is non-syndromic nor creating a faithful animal model that replicates the human disease phenotype. The immediate goal of the present study was to create a tractable *in vivo* model that would allow a further understanding of the requirement for dolichol homeostasis and DHDDS activity in retinal PR cells specifically. This targeted approach was taken because (1) global deletion of *Dhdds* likely would be embryonic lethal, and (2) PRs represent the predominant cell type affected in the RP59 retinal degeneration. Such targeted gene ablation in rods is best achieved by using the *Dhdds*^flx/flx^ iCre^+^ model as employed here. Also, the synthesis of dolichol and its derivatives requires the activity of two enzymes--- DHDDS and Nogo-B receptor (NgBR)---functioning together as a heterodimeric complex ([@bib58], [@bib57]). In this study, we have modeled the effect of PR-specific deletion of the gene that encodes only one of the two heterodimeric partners. In addition, this cell type-specific targeted gene ablation occurs only in rod PRs and is dependent on the onset of opsin gene expression (the promoter driving Cre expression), which starts at PN day 4--7 (after the onset of expression of the transcription factor *Nrl*, which determines rod cell fate). This scenario is significantly different from what occurs in human patients with RP59: first, RP59 involves DHDDS point mutations, rather than gene ablation; second, those mutations are found in every cell type throughout the retina (and the entire body), rather than being restricted just to rod cells; third, the global expression of mutant DHDDS in humans is initiated *in utero* during early embryogenesis, rather than commencing after birth.

The lack of an observable defect in protein *N*-glycosylation in the retina in the *Dhdds*^flx/flx^ iCre^+^ model may be attributed to at least two factors: (1) the other heterodimeric partner, NgBR (gene: *Nus1*), required for dolichol synthesis (which, presumably, remains active in the absence of Dhdds) may be able to at least partly take over the role of Dhdds (i.e., enzyme activity is impaired, but not completely lost) and/or (2) the dolichol synthesized in PR cells (or their precursors) *before* onset of Cre-recombinase expression may persist and be sufficient to support protein *N*-glycosylation even *after Dhdds* has been ablated in the rod cells. The lack of suitable reagents or methods to directly study the distribution and turnover rates of dolichol and its derivatives at the single cell and subcellular levels also presents a further impediment to obtaining a more complete understanding of exactly how PR-specific ablation of *Dhdds* alters this aspect of isoprenoid homeostasis in those cells.
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### Materials Availability {#sec3.5.2}
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### Data and Code Availability {#sec3.5.3}

Not applicable.
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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